Document is current
Any future updates will be listed below
-
Authors
Adamik, Juraj
Munson, Paul V.
Hartmann, Felix J.
Combes, Alexis J. https://orcid.org/0000-0002-9110-6542
Pierre, Philippe https://orcid.org/0000-0003-0863-8255
Krummel, Matthew F. https://orcid.org/0000-0001-7915-3533
Bendall, Sean C. https://orcid.org/0000-0003-1341-2453
Argüello, Rafael J. https://orcid.org/0000-0001-9785-3883
Butterfield, Lisa H. https://orcid.org/0000-0002-3439-9844
-
Funding
Funding for this research was provided by:
Parker Institute for Cancer Immunotherapy
- License Information
-
More Information
Article History
Received: 15 October 2021
Accepted: 20 August 2022
First Online: 2 September 2022
Competing interests
: L.H.B. declares the following unrelated competing interests: Calidi Scientific and Medical Advisory Board, April 6, 2017-present; KaliVir, Scientific Advisory Board, 2018–2021; Torque Therapeutics, Scientific Advisory Board, 2018–2020; Khloris, Scientific Advisory Board, 2019-present; Pyxis, Scientific Advisory Board, 2019-present; CytomX, Scientific Advisory Board, 2019-present; DCprime, Scientific Advisory Board meeting, Nov. 2020; RAPT, Scientific Advisory Board, 2020-present; Takeda, Scientific Advisor, 2020-present; EnaraBio scientific advisor, Feb. 2021. There are restrictions to the commercial use of SCENITH due to a pending patent application (PCT/EP2020/WO2020212362A1). The remaining author declare no competing interests.
